<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176681</url>
  </required_header>
  <id_info>
    <org_study_id>5706</org_study_id>
    <nct_id>NCT02176681</nct_id>
  </id_info>
  <brief_title>A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is a major concern for dialysis units, as it is now the most common cause of
      end-stage renal disease in France. In 2010 at initiation of dialysis treatment, more than one
      patient out of two had at least one cardiovascular disease and 40 % diabetes (94 % Type 2
      diabetes) and especially in East part of France.

      Diabetic patients on dialysis have a high burden of morbidity and mortality, particularly
      from cardiovascular disease. Tight glycaemic and blood pressure control in diabetic patients
      has an important impact in reducing risk of progression nephropathy. Data are scarce on how
      diabetes should best be treated in dialysis patients. The evidence for improving glycaemic
      control in patients on dialysis having an impact on mortality or morbidity is sparse. Indeed,
      many factors make improving glycaemic control in patients on dialysis very challenging,
      including therapeutic difficulties with hypoglycaemic agents, monitoring difficulties,
      dialysis strategies that exacerbate hyperglycaemia or hypoglycaemia.

      Standard oral drugs therapy for hyperglycaemia (eg, metformin, sulfonylureas, ) are
      contraindicated in patients on dialysis. Thus insulin has been the mainstay of treatment.
      Newer therapies for hyperglycaemia, such as gliptins and glucagon-like peptide-1 analogues
      have become available, but until recently, renal failure has precluded their use. Newer
      gliptins, however, are now licensed for use in 'severe renal failure', although they have yet
      to be trialed in dialysis patients.

      The investigators study, using continuous glucose monitoring as a new tool for monitoring of
      therapy should provide information on vildagliptin in add on therapy to insulin in this
      population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean glucose value of CGM [M] to be averaged from day 2 and day 3 of CGM</measure>
    <time_frame>up to day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGM parameters at baseline and month 3</measure>
    <time_frame>Other CGM parameters at baseline and month 3</time_frame>
    <description>glucose area under the curve (AUC) for glucose value higher than 7.7 mmol/l
number of glucose values under 3.3 mmol/l
hypoglycaemic events at baseline, month 3
number of minor hypoglycaemic events per month
number of major hypoglycaemic events at month 3
number of nocturnal hypoglycaemic events per month
variability glycemic index: MAGE, CV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycaemic events</measure>
    <time_frame>Hypoglycaemic events at baseline, month 3</time_frame>
    <description>hypoglycaemic events at baseline, month 3
number of minor hypoglycaemic events per month
number of major hypoglycaemic events at month 3
number of nocturnal hypoglycaemic events per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean HbA1C and Glycated albumin</measure>
    <time_frame>HbA1C and Glycated albuminat baseline and month 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Haemodialyzed, Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Insulin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use the usual frequency and dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin and Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vildagliptin 50 mg/day during 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin (Galvus)</intervention_name>
    <description>Use Vildagliptin (50 mg/day) added to insulin during 3 months</description>
    <arm_group_label>Insulin and Vildagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin</description>
    <arm_group_label>Insulin alone</arm_group_label>
    <arm_group_label>Insulin and Vildagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated by haemodialysis for more than 3 months with 1g/L glucose in
             dialysate fluid

          -  Patients treated by stable doses of insulin (any regimen) for Type 2 diabetes without
             any oral antidiabetic agent

          -  Age &gt; 18 years

          -  TGO, TPO and lipase &lt; 3x ULN

          -  effective means of contraception

        Non-inclusion Criteria:

          -  Blood transfusion in the 2 previous months

          -  Life expectancy less than 1 year

          -  Chronic inflammatory disease

          -  Steroid treatment &gt; 5mg/day

          -  Cancer (evolutive or requiring chemotherapy or radiotherapy) with the exception of
             breast intraductal carcinoma operated

          -  Patient waiting for programmed surgery

          -  History of cardiovascular disease (stroke, coronary heart disease, hospitalization for
             heart failure) in the 4 previous months

          -  Patients suffering from stage 3 and 4 cardiac insufficiency

          -  Non-compliant patients

          -  History of pancreatitis

          -  History of angioedema

          -  Hypersensitivity to the active substance or to any of the excipients of Galvus®

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François CHANTREL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AURAL - Mulhouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre KLEIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Colmar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier IMHOFF, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AURAL Clinique Saint-Anne de Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre KLEIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AURAL - Colmar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique FLEURY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de Valenciennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno VERGES, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe ZAOUI, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe ZAOUI, MD-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>AGDUC - Grenoble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriel CHOUKROUN, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire, Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joëlle CRIDLIG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie BOROT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Besançon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François CHANTREL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de Mulhouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier IMHOFF, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Sainte Anne de Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian KUNTZ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AURAL de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AURAL Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AURAL Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AURAL Clinique Sainte Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AURAL Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

